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Abstract
Background: The use of dietary supplements (DS) is common among persons with dementia. Direct risks
associated with DS use include adverse events and DS-drug interactions. A direct risk is a risk caused by the
treatment itself. Indirect risks are related to the treatment setting, such as the conditions of use, and not to the
treatment itself. Because dementia symptoms may reduce a person’s ability to cope with the administration of
DS, the use of DS may pose a threat to safety as an indirect risk. The aim of this study was to describe the extent
of DS use among persons with dementia in ambulatory care and to identify some relevant direct and indirect
risks related to DS use.
Methods: We conducted a survey among 151 persons with dementia attending an outpatient memory clinic in
Northern Norway. Study measurements included: the participants’ characteristics, cognitive functioning, functioning
in the activities of daily living (ADL), and the use of DS and prescription drugs (PD). We assessed direct risks by
evaluating potential DS-drug interactions and indirect risks by evaluating the conditions under which it was used.
Results: Forty-six percent (n = 70) of the persons with dementia used DS. Ninety-seven percent (n = 147) used
PD. We found potentially clinically relevant DS-drug interactions representing a direct risk in eight persons with
dementia (11% of users). While only 36% (n = 26) of the participants received assistance with the administration
of DS, 73% (n = 106) received assistance with the administration of PD. Persons with dementia living alone were
at risk of not receiving assistance, as home care service seldom was involved in DS administration. Data indicated
that assistance with DS administration was not provided for all persons with dementia in need, representing an
indirect risk to these persons. Only one-third of the persons with dementia and half of the caregivers were aware
of the general risks of adverse events and interactions associated with the use of DS.
Conclusions: Persons with dementia use DS frequently, yet DS use may be associated with direct and indirect
risks to patient safety as potentially clinically relevant interactions were discovered and DS intake often was
unsupervised.
Keywords: Patient safety, Dementia, Dietary supplements, Risk management, Direct risk, Indirect risk, Drug
interactions, Caregivers, Home care services, Cross-sectional survey
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Background
Dementia is a general term for progressive diseases that
lead to loss of mental abilities interfering with and
causing problems in the activities of daily living (ADL).
Alzheimer’s disease is the most common form of de-
mentia, and memory problems are the most common
symptom [1]. Persons affected by dementia become in-
creasingly dependent on assistance throughout the
course of the disease. Because a considerable number of
single persons with dementia continue to live by them-
selves for quite some time, they become increasingly
dependent on home care services. Today, only symp-
tomatic treatment is available for Alzheimer’s disease
[1], resulting in a search for alternative treatments by
persons with dementia and their caregivers. Several diet-
ary supplements (DS) on the market claim to improve
memory problems, but the scientific evidence is sparse
[2–5]. Prevalence estimates of DS use in persons with
dementia range from 27% to 58% [6–10]. The variation
in estimates could be due to heterogeneity in study de-
sign, including the number of participants, the time
period of interest and the types of DS studied.
“Is this Dietary Supplement that my spouse is using,
safe? Can he take it together with his prescription
drugs?” Medical doctors often receive these types of
questions and they rarely have straightforward answers.
Living with persons with dementia can be quite challen-
ging, and caregivers often find themselves unable to con-
trol the situation [11]. For example, one daughter found
half-empty pillboxes containing dietary supplements
(DS), prescription drugs (PD) and over the counter
(OTC) drugs all around her mother’s apartment, even
inside the microwave oven. Similar examples are well
known among caregivers of persons with dementia and
these types of questions and worries prompted the con-
duct of this study. DS are often labeled as “natural” and
are therefore regarded as safe products by many con-
sumers. DS can nonetheless cause harm through ad-
verse events [12, 13], and even lethal cases have
occurred [14, 15]. Their potential to interact with PD is
also of concern [16, 17].
A direct risk is a risk related to the treatment itself
such as adverse events and DS-drug interactions [18, 19].
Moreover, there are other threats to patient safety from
DS use, such as variability in quality and content; for
example, adulterants in the form of pharmaceuticals
have been found [20, 21]. Another concern is the pro-
found lack of studies documenting safety, tolerability,
and efficacy [22]. Another safety issue is a striking lack of
reliable information about DS-drug interactions [23, 24].
This, together with the risk of overdosing or forgetting
to take the daily dose of treatment, poses a considerable
threat to patient safety. Factors which are not directly re-
lated to the DS itself, are often referred to as “indirect
risk factors.” By definition, indirect risks are risks related
to the treatment setting, instead of the treatment itself
[18, 19]. Indirect risks are often caused by acts of omis-
sion and can include obtaining insufficient information
about the patients’ medical history, inadequacies in diag-
nostic testing, as well as persons not receiving needed
drugs or not receiving adequate help with the adminis-
tration of their drugs [25]. Indirect risks from the use
of complementary and alternative medicine (CAM) in
general can also include delayed diagnosis and a lack of
awareness among CAM practitioners of the therapeutic
limitations of CAM [19, 26].
With regard to persons with dementia, disease-related
cognitive problems may increase the indirect risks from
DS usage (Fig. 1).
Forgetfulness and impaired judgment may lead to er-
roneous use of DS (or PD and OTC); for instance, per-
sons with dementia may forget that they have already
taken their daily dose of tablets, or they use several DS
with the same ingredients. Moreover, persons with de-
mentia may confuse DS with PD, leading to errors in the
administration of both. Loss of initiative can prevent
persons with dementia from discussing DS use with their
family physician or from obtaining reliable information
about DS at the pharmacy or on the internet. Their re-
duced capability to identify and express their own signs
and symptoms can prevent persons with dementia, es-
pecially in the advanced stages of the disease, from dis-
closing actual adverse events of DS and PD. Moreover,
studies report that few persons with dementia disclose
their use of DS to health care personnel [6–8]. This in-
direct risk situation is particularly threatening because
several indirect risk factors may lead to overdosing;
which invariably increases direct risks such as increased
toxicity.
The degree to which persons with dementia are ex-
posed to indirect risks related to the use of DS is cur-
rently unknown. The lack of awareness and knowledge
about risks from DS among caregivers and health care
professionals, represent an indirect risk to the persons
with dementia [27]. This is also the case of indistinct
lines of responsibility. In particular, little is known about
the involvement of home care services in administering
and dispensing DS to persons with dementia who still
live in their homes. However, home care services visit
persons with dementia in their homes, and can there-
fore, potentially, be the part of the healthcare system
that has the best possibilities to safeguard those who
have decided to use DS. Indirect risks related to health
care personnel’s professional conduct may be an access-
ible window for intervention within the risk structure of
DS use in persons with dementia.
The aim of this study was to describe the extent of DS
use among persons with dementia in ambulatory care
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and to identify direct and indirect risks related to DS
use. More specifically, we wanted to investigate whether
persons with dementia received assistance with the
administration of DS and PD and relate this to vul-
nerability factors in these persons.
Methods
Study population
We conducted a questionnaire-based survey of persons
with dementia attending an outpatient memory clinic in
North Norway from November 2011 to end of October
2013. We included all consecutive patients who met the
ICD-10 criteria for dementia and who visited a neurolo-
gist (HR) for a regular neurological follow-up. To ensure
reliable responses, only persons with dementia who were
accompanied by a caregiver, who could supply informa-
tion, were included. If the person with dementia brought
several caregivers, the one closest to the person with de-
mentia was defined as the main caregiver. For two per-
sons who brought no relatives, health care professionals
familiar with the persons were defined as caregivers. We
excluded four persons with dementia because of severe
communication problems with their caregivers. The
caregivers were not assessed, but the communication
problems were judged to be caused by cognitive impair-
ment, most likely in combination with profound hearing
loss, which was not properly compensated by a hearing
aid. The numbers of patient visits to the clinic before in-
clusion varied, as did the type of dementia.
Survey development and implementation
The study was initiated after several caregivers had
raised concerns about DS-drug interactions and about
incorrect use of DS by their relatives with dementia.
Therefore, these topics were our main concern. HR and
TG constructed the questionnaire based on previous
studies and on their experience from clinical practice at
a memory clinic and from a drug information center,
respectively. We strived for simple wording and open-
ended questions. The feasibility of the instrument was
tested on five persons with dementia prior to the start of
the study. Some parts of the current survey were part of
the routine consultation such as age, gender, whether
the patients lived alone, whether they received help from
homecare, MMSE-NR and RDRS-2, list of PD and OTC
and whether the person with dementia received help
with the administration of PD. Twelve additional ques-
tions were designed exclusively for this survey. The pa-
tient/caregiver received altogether 16 questions, nine
open-ended and seven yes/no questions. Seven of these
questions are not included in this publication because the
content of data would exceed the scope of one article.
These data will be published later. All participants were
asked about their current use of DS, and users were fur-
ther asked to specify the product names and where they
had procured their DS (pharmacy, merchandiser/retailer
of dietary supplements, grocery store, internet or tele-
phone sale, direct from CAM therapist). We also asked
who had initiated the use (patient themselves, spouse,
Fig. 1 Risks related to use of dietary supplements in persons with dementia. Abbreviation: DS, dietary supplements
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other relatives, health care personnel, retailers), and who
secured correct administration (patient themselves, spouse
or relatives, home care service). We asked all persons with
dementia and all caregivers if they knew that dietary sup-
plements might have potential negative effects such as
adverse events and interactions with prescription drugs.
This was a general question and not related specifically
to the DS used by some of the participants.
It was important for us to involve the persons with de-
mentia themselves as much as possible. We therefore
designed the questionnaire as a structured face-to-face
interview where both the person with dementia and his
or her caregiver were present during the interview. The
interviews were performed by HR. If the participants did
not understand the questions as they were read out, add-
itional explanations were given. The definition of DS
(e.g., that it includes herbs, vitamins, minerals and
other compounds, or a mixture of different ingredients)
was explained to all participants. They were also given
examples of common brand names of DS during the
interview. A non-judgmental, open attitude toward the
use of DS was maintained during the interview. In most
cases, both the persons with dementia and the care-
givers provided the answers, but in cases of severe de-
mentia, it was mostly the caregivers who answered the
questions. If persons with dementia and caregivers pro-
vided divergent answers or if they both reported uncer-
tainty, we asked them to check at home and contact us
later by telephone. When there was persistent disagree-
ment/uncertainty, the answers were left blank. The re-
sponse was oral and the answers were written down
and categorized.
Cognitive assessment
All persons with dementia were assessed using the
Mini-Mental Status Examination-Norwegian Revision
(MMSE-NR) [28, 29], and, with the assistance of the
caregivers, using the Rapid Disability Rating Scale-2
(RDRS-2) [30]. The aim was to collect up-to-date infor-
mation about persons with dementias’ cognitive- and
ADL functions. The RDRS-2 scale ranges from 21 to 84
points; a score of 21 indicate normal ADL function,
while a score of 84 indicates complete dysfunctionality.
MMSE-NR screens people for difficulties in cognitive
function with scores ranging from 0 to 30. A score
below 24 is suggestive of cognitive problems, such as in
dementia, but can also be caused by other reasons;
values in the range of 25–27 might represent early
stages of dementia. Scores above 28 indicate normal
function with some exceptions such as frontotemporal
dementia in the initial stages of the disease [31]. Per-
sons with higher education could achieve higher MMSE
scores even in the presence of dementia [32]. We did
not assess for educational level.
Direct risk assessment
Direct risk of DS is harm caused by the products
themselves. In this study, we assessed only DS-drug
interactions and not adverse events. Lists of individual
persons’ PD, DS and OTC were collected and sent an-
onymously to the Regional Pharmacovigilance Center
North Norway (RELIS North Norway) for assessment
of DS-drug interactions. The Natural Medicines Com-
prehensive Database, Medline and the Norwegian
RELIS database were used to identify potential clinic-
ally relevant DS-drug interactions. Due to time con-
straints during the interview, we made no assessment
of potential clinical correlations from potential DS-
drug interactions. The survey took place in an out-
patient clinic setting and it was too time consuming
to assess DS–drug interactions during the consult-
ation. As several of the participants had travelled
quite a distance to get to the clinic, we did not in-
clude another patient visit in the survey. Our out-
patient clinic covers a wide geographical area
including several ferry routes, with the longest travel-
ing distance of nearly 400 km. The memory clinic
contacted the home care service or the family phys-
ician in most cases to obtain an updated list of the
persons with dementia’s PD and OTC.
Indirect risk assessment
Indirect risks from DS use are related to the condition
of use. In this study, we investigated to what degree per-
sons with dementia received assistance administering
DS, in general and according to their cognitive function.
We also investigated the knowledge of risks, and
whether knowledge of risks influenced the use of DS, or
help with administering DS.
Definition of dietary supplements
We used the definition of DS from the Dietary Supple-
ment Health and Education Act of 1994 paragraph 3a
[33]. The definition states that a DS is a product con-
taining one or more of the following: “a vitamin, a min-
eral, an herb or other botanical, an amino acid, or a
dietary substance for use by man to supplement the
diet by increasing the total dietary intake; or a concen-
trate, metabolite, constituent, extract, or combination
of these ingredients.” We excluded pure vitamin sup-
plements that were used to treat a diagnosed deficiency.
We also excluded untreated edible oils, herbs used as
spices, food bars and beverages such as teas. This was
because our main interest was in supplements that
could be confused with drugs by the persons with de-
mentia and administered by home care services. None
of the participants reported using supplements in other
administration forms than tablets.
Risvoll et al. BMC Complementary and Alternative Medicine  (2017) 17:261 Page 4 of 12
Ethics
The study was approved by the Regional Committee for
Medical and Health Research Ethics North, reference
number: 2011/1705. An employee at the outpatient clinic,
who was not involved in patient care, presented the study
details and obtained written consent from each participant
and caregiver before consultation and data collection.
Statistics
Data were analyzed using IBM SPSS (Statistical Package
for the Social Sciences) version 22.0 (IBM Corporation,
Armonk, NY, US) for Windows. We present descriptive
statistics such as absolute and relative frequencies,
means and standard deviations. We applied an independ-
ent Student’s t-test for continuous variables and Pearson’s
chi-square or Fisher’s exact tests for categorical variables.
We used logistic regression for binary data to analyze the
associations between the frequency of persons with de-
mentia receiving assistance with DS administration and
the initiators of DS use in these persons. Significance level




We included 151 persons with dementia, mean age was
73.3 years (range 20–90), average MMSE-NR was 19.6
(range 0–29). The youngest participant had genetically
and clinically verified Juvenile Huntington’s disease. The
person with MMSE-NR score of 29 had the diagnosis
frontotemporal dementia. Sixty-three percent were women
and 32% lived alone. All responders were of Scandinavian
heritage. The caregivers were mostly spouses (51%) or
children (35%), and more seldom other relatives, friends or
health care professionals (14%). Three persons declined
to join the study. Twelve other persons were excluded
for different reasons (e.g. HR judged the persons with
dementia as being too exhausted). The overall response
rate was 90%.
Seventy persons with dementia (46%) reported the use
of DS. On average, they used 1.7 DS (range 1–6). Fish
oils were the most commonly used DS (40 persons,
57%), followed by various mixed herbal supplements (29
persons, 41%) and vitamin and mineral supplements (28
persons, 40%). Thirty-two (46%) of the users consumed
more than one DS product.
As Table 1 shows, the users and non-users of DS were
similar with regard to age, gender, living conditions, and
use of PD in general and dementia drugs in particular.
Even though users of DS showed less severe reduction in
cognitive function measured by MMSR-NR and a trend
towards better ADL functioning measured by RDRS-2
compared with non-DS-users, both groups showed clear
signs of cognitive impairment.
In most cases, the persons with dementia did not ini-
tiate the use of DS. In 20 cases (29%) the persons with
dementia took the initiative themselves, while in 15
cases (22%) the spouse took the initiative, in 14 cases
(20%) other relatives, in 10 cases (14%) health care
personnel, and in 10 cases (14%) DS-retailers took the
initiative. Data were missing from one participant.
Persons with dementia had purchased DS on the
internet or through telephone sale in 26 cases (37%), at
pharmacies in 25 cases (36%), at DS-retailers in 16
cases (23%), and at grocery stores in 13 cases (19%).
Some persons had purchased their DS at several places.
Table 1 Comparison between users and non-users of dietary supplements
Persons with dementia’s
characteristics
Users of DS Non-Users of DS Total population
n = 70 n = 81 p-value n = 151
Age, year (mean (±SD)) 72.7 (11.2) 73.7 (9.8) 0.547 73.3 (10.4)
Women (n (%)) 49.0 (70.0) 46.0 (56.8) 0.094 95.0 (62.9)
Living alone (n (%)) 23.0 (32.9) 25.0 (30.9) 0.793 48.0 (31.8)
Home care services (n (%)) 31.0 (44.3) 33.0 (40.7) 0.660 64.0 (42.4)
Numbers of PD (mean (±SD)) 4.7 (3.4) 4.4 (2.6) 0.582 4.6 (3.0)
Persons using dementia drugs (n (%)) 29.0 (41.4) 41.0 (50.6) 0.259 70.0 (46.4)
Numbers of OTC *(mean (±SD)) 0.8 (0.8) 0.7 (0.7) 0.334 0.7 (0.7)
MMSE-NR score (mean (±SD)) 21.7 (4.5) 17.8 (6.3) <0.001 19.6 (5.8)
RDRS-2 score (mean (±SD)) 34.5 (8.8) 38.5 (11.5) 0.019 36.7 (10.5)
Abbreviations: DS dietary supplements, SD standard deviation, PD prescription drug, OTC over-the-counter drug, MMSE-NR Mini Mental State Examination-Norwegian
Revision, RDRS-2 Rapid Disability Rating Scale-2
*Data are missing from two persons
The RDRS-2 scale range from 21 to 84, where a score of 21 points indicates normal function in activities of daily living and a score of 84 points indicate complete
dysfunctionality. The MSEE-NR scale range from zero to 30, where 30 points indicate normal cognitive function. Statistics are independent Student’s t-test for con-
tinuous variables such as age, numbers of PD and OTC, MMSE-NR and RDRS-2. Statistics are Pearson’s chi-square or Fisher’s exact tests for categorical variables
such as gender, living alone, receiving help from home care service and using dementia drugs. Bonferroni adjusted α was 0.05 / 9 resulting in α < 0.006. Signifi-
cant comparisons after adjustment are printed bold
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In three cases (4%), a relative provided the DS for free.
Two of these relatives were DS retailers.
Direct risks related to use of DS
Of the 147 persons with dementia who used PD, two of
these only used vitamin B12 injections every third
month. On average, the persons used 4.6 PD (range 0–
17) and 0.7 OTCs (range 0–3). We identified poten-
tially clinically relevant interactions between DS and
PD/OTCs in eight persons (11%). In four persons these
interactions involved anticoagulants, and in four per-
sons antihypertensives. Boswellia serrata, Vaccinium
macrocarpon and omega-3 could possibly interact with
warfarin. Atenolol was combined with lutein, Camellia
sinensis, Bacopa monnieri, Capsicum annum, Crocus
sativus and procyanidolic oligomers. Amlodipine was
combined with astaxanthin, Panax ginseng, Punica
granatum, lutein and Boswellia serrate. Metoprolol was
combined with pomegranate, Cordyceps sinensis and
Panax ginseng. One participant suffered from tachycar-
dia, which could have been negatively affected by her
DS use. She used a DS (in tablet formulation) contain-
ing Camellia sinensis among several other ingredients.
Camellia sinensis contains high amounts of caffeine
and also theophylline [34], which may lead to tachycar-
dia. At the same time, this person used a beta-blocker
for her tachycardia. In this case we recommended that
the use of that particular DS was ended. In addition,
one participant used DS causing a daily intake of vita-
min D, chromium and copper above the recommended
dietary intake, RDI [35, 36].
Indirect risks related to use of DS
Only 26 out of 70 persons with dementia (37%) received
assistance administering their DS, compared to 106 per-
sons out of 145 (73%) who received assistance adminis-
tering their PD. Two persons in the PD group did not
depend on daily assistance, as their only medications
were vitamin B12 injections every third month. Living
alone was associated with not receiving assistance with
DS; this was not the case for persons with dementia who
used PD (Table 2). Persons with dementia who received
assistance with PD had lower MMSE-NR scores and
higher RDRS-2 scores as an indication of more advanced
dementia. After the Bonferroni correction, this differ-
ence was no longer statistically significant for MMSE-
NR score in participants who received assistance with
DS, although there was a significant difference in their
RDRS-2 score.
Several persons who did not receive assistance with
DS and PD had MMSE-NR and RDRS-2 scores indi-
cating that it was questionable whether they were able
to handle the administration of DS and PD on their
own. The lowest MMSE-NR score was 13 in both
groups, and the highest RDRS-2 score was 45 in par-
ticipants who did not receive assistance with the ad-
ministration of DS, and 39 in participants who did
not receive assistance with PD. Fifty percent of the 44
persons with dementia who administered their DS
themselves had MMSE scores below 24 points. Fifty-
seven percent of the 39 persons with dementia who
administered their PD themselves had MMSE scores
below 24 points.
Table 2 Characteristics of adults with dementia receiving assistance with dietary supplements or prescription drugs
Assistance with DS No assistance with DS Assistance with PD No assistance with PD
Numbers of persons with dementia n = 26 n = 44 p-value n = 106** n = 39** p-value
Age, year (mean (±SD)) 76.8 (8.1) 70.3 (12.1) 0.017 74.5 (10.9) 70.4 (8.9) 0.040
Women (n (%)) 16.0 (61.5) 33.0 (75.0) 0.235 65.0 (61.3) 27.0 (69.2) 0.380
Living alone (n (%)) 3.0 (11.5) 20.0 (45.5) 0.004 35.0 (33.0) 10.0 (25.6) 0.394
Home care services (n (%)) 14.0 (53.8) 17.0 (38.6) 0.216 64.0 (60.4) 0.0 - <0.001
Numbers of PD (mean (±SD)) 5.5 (2.9) 4.3 (3.7) 0.161 5.4 (2.9) 3.0 (2.4) <0.001
Persons using dementia drugs (n (%)) 12.0 (46.2) 17.0 (38.6) 0.537 54.0 (50.9) 16.0 (41.0) 0.289
Numbers of OTC (mean (±SD))* 0.7 (0.8) 0.8 (0.8) 0.604 0.7 0.7 1.0 0.7 0.047
MMSE-NR (mean (±SD)) 20.1 (4.2) 22.6 (4.5) 0.021 18.5 (6.1) 22.4 (4.2) <0.001
RDRS-2 (mean (±SD)) 38.9 (9.5) 32.0 (7.3) 0.001 40.2 (10.0) 27.7 (5.3) 0.001
Abbreviations: DS dietary supplements, PD prescription drug, SD standard deviation, OTC over-the-counter drug, MMSE-NR Mini Mental State Examination-Norwegian
Revision, RDRS-2 Rapid Disability Rating Scale-2
*Data are missing from two participants
**Six respondents did not use PD regularly. Four respondents used no PD. Two respondents, who used only vitamin B12 injection, were not included in the 145
respondents that used PD, as they were independent on daily assistance
Note that the RDRS-2 scale range from 21 to 84, where a score of 21 points indicates normal function in activities of daily living and a score of 84 points indicate
complete dysfunctionality. The MSEE-NR scale range from zero to 30, where 30 points indicate normal cognitive function
Statistics are independent Student’s t-test for continuous variables such as age, numbers of PD and OTC, MMSE-NR and RDRS-2. Statistics are Pearson’s chi-square
or Fisher’s exact tests for categorical variables such as gender, living alone, receiving help from home care service and using dementia drugs. Bonferroni adjusted
α was 0.05/9 resulting in α ≤ 0.006. Significant comparisons after adjustment are printed bold
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Two out of twelve persons with dementia who used anti-
coagulants did not receive assistance with drug administra-
tion. Both were in an early stage of dementia as measured
by MMSE-NR and RDRS-2 (lowest MMSE-NR score was
20, highest RDRS-2 score was 30). One of these persons
also used digoxin, three antihypertensives and a DS contain-
ing Boswellia serrata, astaxanthin and omega-3-fatty acid.
Caregivers were most frequently assisting with DS,
and home care services with PD. Home care services
were seldom involved in assisting persons with dementia
with the administration of DS (Fig. 2). In 17 cases, per-
sons with dementia received home care services for PD,
without the home care service being involved in the ad-
ministration of these persons’ DS (Table 2). A direct
comparison between those who received help with the
administration of DS and those who received help with
the administration of PD can not be made because of
overlap between those two populations.
Spouses and other relatives were the most frequent
initiators of DS use. There was a relationship between
who initiated use and receiving assistance with DS.
When spouses or health care personnel initiated DS use,
persons with dementia were more likely to receive assist-
ance with the administration of the DS (Table 3).
Fig. 2 Assistance with administration of dietary supplements and prescription drugs related to function. Abbrevation: DS, dietary supplements;
PD, prescription drugs; ADL, activities of daily living; MMSE-NR, Mini Mental State Examination-Norwegian Revision; RDRS-2, Rapid Disability Rating
Scale-2; SD, standard deviation. Two persons with dementia, who used only vitamin B12 injection, were not included in the 145 persons that
used PD, as they were not dependent of daily assistance. Note that Fig. 2 demonstrate descriptive data. The RDRS-2 scale range from 21 to 84,
where a score of 21 points indicates normal function in activities of daily living and a score of 84 points indicate complete dysfunctionality. The
MSEE-NR scale range from zero to 30, where 30 points indicate normal cognitive function
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Awareness of risk
Forty-eight persons with dementia (32%) and 77 care-
givers (51%) said they were aware that use of DS might
increase a general risk for adverse events and interac-
tions with PD. Data were missing from four participants.
Participants’ DS use did not differ depending on know-
ledge of risk among caregivers and persons with demen-
tia. In the 78 cases where caregivers knew about the risk
for adverse events or DS-drug interactions, 35 persons
with dementia used DS (44%); in the 69 cases where
caregivers were not aware, 33 (48%) used DS (p = 0.720,
Pearson’s χ2 0.129, df 1). Among persons with dementia
who used DS, caregivers’ knowledge of risk did not in-
fluence help with administration of DS. If caregivers
knew about the risk for adverse events or DS-drug in-
teractions, 16 out of 35 (46%) users of DS received
help with the administration; if caregivers were not
aware, 10 out of 33 (30%) users of DS received help
with the administration, (p = 0.19, Pearson’s χ2 1.708,
df 1).
Discussion
The use of DS was common among persons with de-
mentia. With regard to direct risks, only a minority of
the persons with dementia were aware of the potential
risk of adverse events and/or interactions from DS. Al-
though only few persons with dementia used combina-
tions suggesting clinically relevant DS-drug interactions,
the ones we found were potentially harmful.
The persons with dementia did not receive the same
degree of assistance with their DS as with their PD. Two
thirds of the persons received assistance with the admin-
istration of their PD, while only one third received assist-
ance with the administration of DS. Additionally, home
care services were minimally involved in DS monitoring.
Use of DS
No previous studies have addressed the use of DS in per-
sons with dementia in a Norwegian setting, but the
estimated prevalence of DS use among Norwegians in
general ranges from 44% to 74% [37, 38]. Almost half of
the persons with dementia in the current study reported
the use of DS, which is consistent with studies on per-
sons with dementia from Canada, Germany, India and
the US [6–10] and also consistent with the use of DS in
the general Norwegian population [38].
The only difference between users of DS and non-
users were signs of better cognitive function in users.
The higher frequency of DS use among persons with less
advanced dementia, indicated by higher MMSE-NR and
a trend towards lower RDRS-2 scores, is in line with
previous research [9]. Our cross-sectional analysis does
not allow for causal interpretations. Possible explana-
tions for the result could be that some DS actually slow
down cognitive decline (although not scientifically docu-
mented), or that people with dementia tend to stop
using DS as the disease progresses or a combination of
both. Reasons for discontinuing a DS could be that per-
sons with dementia stop buying it because of increased
forgetfulness or loss of initiative. Other reasons might be
increasing reluctance to take DS or tablets in general, or
that the persons with dementia and their caregivers lose
faith in DS, if the effect that they hoped for fails.
Direct risks of DS use
The direct risks caused by potentially clinically relevant
DS-drug interactions in 11% in the DS users gives rea-
son for concern. The concurrent use of several similar
DS products, such as several fish oils by some of the per-
sons with dementia, in combination with anticoagulants,
should be mentioned. Although a risk of increased
bleeding from taking omega-3-fatty-acid supplements
has been suggested, excessive bleeding due to inhibition
of platelet function has not been demonstrated in clin-
ical studies [39]. The clinical importance of combining
omega-3-fatty acids and drugs that increase the risk of
bleeding (e.g., anticoagulants and aspirin) is debated.
Several of the participants used more than one product
Table 3 The relationship between assistance with DS administration and who initiated the use of DS calculated by logistic
regression analysis
Initiator of DS use Receiving assistance with DS
Yes No Total p-value OR 95% CI
Persons with dementia themselves 4 16 20 0.50 Ref Ref
Spouses 10 5 15 <0.01 6.40 1.47–27.83
Other relatives 2 12 14 0.50 0.53 0.09–3.24
Health care personnel 8 2 10 <0.01 12.80 2.02–81.12
Retailers 1 9 10 0.38 0.04 0.04–3.54
Total 25 44 69*
Abbreviations: DS dietary supplements, OR odds ratio, CI confidence interval
*Data are missing from one participant. Statistics are logistic regression for binary outcome
Significant results are printed in bold. We used an alpha level of 0.05 to evaluate statistical significance
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containing vitamin D, and the total intake exceeded the
RDI of this vitamin. The clinical relevance of this, how-
ever, is uncertain because the given RDI of vitamin D is
an estimate which is well below toxic amounts [36].
Nevertheless, extra caution should be taken in persons
with dementia, as they may be more susceptible to over-
dosing because they may not take their DS as intended.
Other studies have reported potentially clinically relevant
DS-drug interactions in 10–40% of DS users [10, 38, 40].
As the types of DS and the types of drugs used by different
populations could vary over time, a direct comparison be-
tween studies is difficult. As DS are regulated differently
than PD, several factors lead to lack of knowledge about
potential interaction between DS and drugs. Pharmacov-
igilance challenges regarding DS include lack of studies
documenting safety and tolerability, and underreporting
of suspected adverse events [22].
Indirect risks of DS use
Not surprisingly, persons with dementia who had higher
RDRS-2, and lower MMSE-NR scores received more as-
sistance with the administration of PD. Assistance with
DS was related to higher RDRS-2 score, but not to lower
scores in the MMSE-NR. Persons with dementia re-
ceived less assistance when it came to the administration
of DS compared to PD. The persons with dementia who
used DS had slightly better cognitive functioning than
non-users, and we cannot exclude that this could have
affected how much assistance these persons received.
The differences in the cognitive test scores were rather
small, but statistically and clinically relevant [41]. How-
ever, better cognitive functioning cannot be the sole ex-
planation, as some of these persons received assistance
with PD but not with DS. Several studies have set an
MMSE score below 24 as a threshold for persons who
could have trouble with self-administration of drugs [42,
43]. Although both MMSE-NR scores and RDRS-2
scores are rough estimates, the scores of the persons
with dementia who did not receive assistance with the
administration of DS or PD indicate that several of these
persons were in need of assistance. The fact that prob-
ably most of the persons with dementia were in need of
assistance with both DS and PD/OTC, and a relatively
large proportion of the participants did not receive this
assistance, is, in our opinion, the key message from this
study.
Persons with dementia living alone are at a particular
risk of not receiving assistance with DS, as home care
services seldom assisted these persons with DS even
though they frequently assisted with PD. We found that
when health care personnel were the initiators, more
persons with dementia received assistance administering
DS. This suggests that health care personnel’s lack of
awareness of persons with dementias’ DS use is a key
factor in why assistance is not given.
Studies have reported that users of DS rarely inform
health care personnel about their use [6–8, 38]. A likely
reason for this is the belief that the supplements are
harmless [44]. Most of the persons with dementia and
half of the caregivers in the current study were unaware
that DS might cause adverse events and DS-drug inter-
actions. Caregivers’ knowledge of the risks of adverse
events and DS-drug interactions did not influence pa-
tient’s use of DS or assistance with the administration of
DS. We have not investigated the reasons for actions or
omissions on the part of persons with dementia or their
caregivers. It is possible that caregivers believe the bene-
fits from DS outweigh the disadvantages, and that the
potential risk of DS use is too small to necessitate pre-
cautions. Optimistic bias, the belief that one is less likely
than one’s peer to suffer harm, can also lead to the denial
of risks [45].
Inadequate adherence to the administration of DS,
PD and OTC challenge patient safety and requires risk
management [46]. The degree of adherence generally
declines with increasing number of tablets to be taken
[46]. We found that DS users consumed on average 2.1
tablets more per day than non-users (7.2 vs. 5.1 tablets,
respectively). Adherence might therefore be a safety
issue of special concern among DS users.
Although this study focused on DS, it is important to
keep in mind that PD might cause far more damage than
DS when taken incorrectly [47]. It is of concern that two
participants who used anticoagulants, one of them also
digoxin, lacked assistance with the administration of
their PD.
In this study, more than one third of the persons with
dementia bought their DS at pharmacies. Pharmacy em-
ployees possess knowledge of DS and can inform and
advise persons with dementia and their caregivers.
Nonetheless, the majority purchased their DS outside of
the traditional health care service and could therefore
not expect any guidance.
Strengths and limitations of the study
The participation rate in the study was high (90%). All
participants were included prospectively and consecu-
tively from an unselected dementia population, with a
minimum set of exclusion criteria, to reduce selection
bias and maintain external validity. The dementia popu-
lation in this study was comparable to dementia popu-
lations in other studies with regard to age, gender
distribution and level of cognitive function [48]. Our
study population is different from populations in studies
done in more ethnically diverse countries, by being
ethnically homogeneous. This is not due to selection,
but to a high degree of ethnic homogeneity in the elderly
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age groups in our geographic region [49]. Moreover, our
findings are not necessarily generalizable to persons with
dementia who were never referred to specialized health
care, and persons with dementia who do not have a
caregiver, as these groups were not included in our
study. The participants were recruited from a Norwegian
outpatient clinic and the results should be interpreted
on the background of the particularities of the Norwegian
healthcare system. However, the general problem of direct
and indirect risks associated with DS use in persons with
dementia will probably be relevant in other health care
structures as well.
The study measurements included clinical assessment
as well as face-to-face interviews. When it comes to clin-
ical assessment, we assessed ADL function by the RDRS-2
scale, because this scale was part of the routine assessment
in the memory clinic. The fact that this scale rarely is used
in research is a limitation of our study. Thus, RDRS-2
scale gives a description of ADL function without giving
us the opportunity to compare our results to other studies.
As some of the drug lists were unreconciled, our approach
of contacting home care services and family physicians
ensured data quality. Some underreporting of DS use may
have occurred, and our reported prevalence of use is
therefore a conservative estimate. Furthermore, our study
population was small, even though comparable to earlier
prevalence studies.
Practical implications
Persons with dementia are particularly vulnerable, as the
dementia symptoms reduce their ability to take care of
themselves. It is therefore important to take any in-
creased direct or indirect risk seriously. Health care
personnel and family physicians in particular, should be
aware that around half of the persons with dementia use
DS. Particular emphasis should be placed on persons
with dementia who live alone and persons with dementia
in earlier disease stages, as these subgroups could be less
likely to receive assistance with the administration of
DS. Another concern is co-use of DS, anticoagulants,
and other drugs with a narrow therapeutic window, in
which DS-drug interactions may have serious clinical
consequences.
Caregivers of persons with dementia living alone might
buy and initiate the use of DS without being able to as-
sist in their administration or to be able to ensure safe
use. It may therefore be advisable for family physicians
and home care services to discuss DS with caregivers,
particularly when the persons with dementia live alone.
In order to ensure patient safety, we suggest formalizing
the assistance provided by the health care services related
to DS. Conduction of risk assessment including evaluation
of DS-drug interaction should, in our opinion, be
mandatory. Both pharmacists and family physicians are
qualified to take on the assignment. Distinct lines of re-
sponsibility, pointed out by health authorities, would
probably increase patient safety. If the use of DS is safe
and to be continued, health care personnel should se-
cure assistance with DS administration for persons with
dementia in need of assistance. As we observed, there is
a lack of knowledge of the potential risks concerning DS
use among persons with dementia and their caregivers,
thus we suggest that more information is made available
to the public about DS.
Conclusions
The use of dietary supplements was common in the de-
mentia population studied and several sources of direct
and indirect risks were identified. The sources of the
increased risk give reason for concern, and might also be
relevant to other groups of vulnerable persons with
mental or functional challenges, such as old age frailty,
intellectual disability or severe mental illness.
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